Bevacizumab biosimilar - Genor Biopharma

Drug Profile

Bevacizumab biosimilar - Genor Biopharma

Alternative Names: Avastin biosimilar - Genor Biopharma; GB 222

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genor Biopharma
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 24 Oct 2017 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease, Recurrent, Combination therapy) in China (IV) (ChiCTR-IIR17013100)
  • 01 Dec 2016 Phase-I clinical trials in Cancer (In volunteers) in China (IV) (ChiCTR-IIR17011143)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top